Biophan to Exhibit MRI Safe and Image Compatible Technologies at the Medical Design and Manufacturing East Conference and Exposition.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of next-generation medical technology, announced today that they will be exhibiting the Company's MRI safe and image compatible technologies, as well as its other innovative technologies for the medical device industry, at the Medical Design and Manufacturing East Conference on June 6 - 8 at the Jacob K. Javits Convention Center in New York, NY.

Biophan will be exhibiting its solutions for making biomedical devices safe for use MRI, and for reducing the disruption of the quality of MRI images, which some devices create. The solutions include lead designs, filters, and coatings, which can be applied to a wide range of implanted medical devices, as well those used in surgical and diagnostic procedures. The Company is developing solutions for the current limitations of devices when exposed to MRI, since a wide range of medical devices have limited compatibility with MRI. Some devices have safety limitations, such as pacemaker, defibrillator, and neurostimulator leads, and other devices are safe but have visualization problems, such as stents and catheters.

The Company will also exhibit its innovations based on nanomagnetic particles that can enable "active" control of drug eluting implants such as stents and orthopedic implants. This same technology can be used in drug delivery to deliver drugs to target tissues and subsequently activate those drugs, to reduce toxicity.

Biophan representatives Brad Gouldthorpe and Dan Hullihen will also be exhibiting Biophan's cutting-edge innovations for the medical device industry, including the MRI-safe SQUIGGLE(R) motor; an implantable biothermal battery which derives its power from body heat; and the Company's breakthrough, less invasive ventricular assist device, the MYO-VAD(TM), which does not contact circulating blood, reducing the risks of clotting and stroke, bleeding, and infection.

Biophan will demonstrate the latest SQUIGGLE motor, which at 1.5 x 1.5 x 6 mm is the world's smallest linear motor and offers ten times the force and precision of other micro-motors on the market. Biophan Technologies holds the exclusive worldwide distribution rights for medical applications of the SQUIGGLE motor, which is a registered trademark of New Scale Technologies, Inc. The Company believes that the newest SQUIGGLE motor provides unique benefits to the medical device industry due to its small size, compatibility with MRI imaging devices, high precision (better than 100 nm), high force (greater than 20 grams) lower cost and increased efficiency.

The SQUIGGLE motor uses a threaded nut and screw to create precise linear movement in a small space. Piezoelectric ceramics create ultrasonic vibrations in the nut, causing the screw to rotate and provide linear motion with high force and precision.

"We believe this tiny ceramic motor is an important breakthrough in medical technology," stated John Lanzafame, Biophan COO. "The SQUIGGLE's unique combination of features makes it an ideal replacement motor for devices such as drug pumps, for cryogenic applications, and for any device that requires MRI compatibility, such as MRI positioning systems and contrast agent infusion pumps. It will assist in Biophan's vision of enabling a new class of MRI safe and image compatible medical devices."

About New Scale Technologies, Inc.

New Scale Technologies, Inc. (www.newscaletech.com) makes miniature ceramic motors that enable our customers to create smaller products and research tools. Our piezoelectric SQUIGGLE motors are smaller, more efficient and more precise than conventional motors. With very few parts and no gears, this patented piezoelectric motor design uses ultrasonic vibrations to create precise linear motion. New Scale's miniature motors are compatible with extreme environments including vacuum, very low (sub-Kelvin) temperatures, and high magnetic fields.

SQUIGGLE is a registered trademark of New Scale Technologies, Inc.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI), problems which the Company has solved and begun to license to leading device manufacturers. The Company's mission has expanded to provide other technologies which will improve the delivery of healthcare. Biophan's technologies enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. The Company is helping to commercialize the MYO-VAD(TM), a novel, MRI-compatible ventricular assist device which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of over 200 U.S. and foreign patents, licenses, or applications. This total includes 56 issued U.S. patents, and over 100 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.